MedTrace Logo

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke

NCT05993884 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-08-12

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

iEPCs

Patients receive iEPCs IV with the single dose

DRUG

Placebo

Patients receive placebo IV with a single dose

Sponsors & Collaborators

  • Linfen Central Hospital

    collaborator UNKNOWN

  • Peking University Third Hospital

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Linyi People's Hospital

    collaborator OTHER

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-24
Primary Completion
2025-04-15
Completion
2025-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05993884 on ClinicalTrials.gov